A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.

‘A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial’ by David Erritzoe et al. was published in Nature Medicine at 16:00 UK time on ...

The Rapid RCT Lab has worked with 16 departments across NYU Langone and completed 47 trials, and we are currently involved in ...

More cases of colorectal cancer are detected at an early stage with screening. This is according to new research based on data from over 278,000 60-year-olds, who were randomly selected to undergo one ...

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to ...

Randomized, blinded clinical study evaluating injectable autologous hair follicle secretome in patients with androgenic ...

Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...

The Rapid RCT Lab is a nationally-leading team conducting innovative, rapid RCTs to improve the delivery of services at the ...

GRAIL's topline results from the NHS-Galleri trial were a clear disappointment with no major implications on ...